United Therapeutics | UTHR - Current Liabilities


United Therapeutics reported $624.3M in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
Amarin USD 175.14M 10.94M Sep/2026
Ardelyx USD 127.8M 4.42M Sep/2026
Baxter International USD 3.81B 218M Sep/2026
Bayer EUR 29.4B 2.87B Sep/2026
BioCryst Pharmaceuticals USD 195.83M 13.02M Sep/2026
Biogen USD 3.9B 18.7M Sep/2026
BioMarin Pharmaceutical USD 1.6B 59.17M Sep/2026
Emergent BioSolutions USD 651.3M 12.7M Dec/2023
Gilead Sciences USD 12B 982M Sep/2026
GlaxoSmithKline GBP 20.72B 814M Sep/2026
Halozyme Therapeutics USD 476.09M 131.65M Sep/2026
Insmed USD 596.57M 157.83M Sep/2026
Ionis Pharmaceuticals USD 435.29M 119.65M Sep/2026
J&J USD 55.46B 562M Sep/2026
Lexicon Pharmaceuticals USD 9.9M 10.97M Mar/2026
Moderna USD 2.03B 506M Sep/2026
Omeros USD 85.5M 2.28M Jun/2025
Pfizer USD 31.73B 920M Sep/2026
PTC Therapeutics USD 776.08M 5.01M Sep/2026
Regeneron Pharmaceuticals USD 6.2B 671.5M Sep/2026
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sarepta Therapeutics USD 656.35M 153.44M Sep/2026
Teva Pharmaceutical Industries USD 15.42B 221M Sep/2026
United Therapeutics USD 624.3M 16.5M Sep/2026
Vertex Pharmaceuticals USD 5B 1.06B Sep/2026